CompletedPHASE1, PHASE2NCT00407355

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

Studying Central retinal vein occlusion

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peter A Campochiaro, MD
Principal Investigator
Peter A Campochiaro, MD
Johns Hopkins University
Intervention
Intravitreal injection of ranibizumab .3 dose(drug)
Enrollment
40 enrolled
Eligibility
18 years · All sexes
Timeline
20062013

Study locations (1)

Collaborators

Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00407355 on ClinicalTrials.gov

Other trials for Central retinal vein occlusion

Additional recruiting or active studies for the same condition.

See all trials for Central retinal vein occlusion

← Back to all trials